secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rubius Therapeutics, Inc. (—)
CIK:        0001709401
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001104659-22-113964
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rubius cuts 82% of staff, CEO and CFO exit, begins strategic review
-------------------------------------------------------------------

- Terminated 42 employees (82% of workforce); expects ~$4.4M in Q4 2022 severance charges.
- CEO Pablo Cagnoni, CFO Jose Carmona, and CLO Maiken Keson-Brookes step down effective Nov 15, 2022.
- Dannielle Appelhans appointed CEO/President and interim CFO; her employment expected to end Jan 31, 2023.
- Board approved plan to review strategic alternatives, including sale or merger of the company.
- Recent termination of $75M credit facility with SLR Investment Corp. cited as factor in financial condition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709401/000110465922113964/0001104659-22-113964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709401/000110465922113964/tm2229359d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-113964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer